The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter ...

However, pulmonary manifestations and symmetric oligoarthritis ... the most likely autoimmune disorder in this case is sarcoidosis. This multisystem granulomatous disorder can involve any organ ...

A heart-lung machine is a piece of medical equipment that temporarily takes over the work of the heart and lungs, circulating oxygenated blood throughout the body. Also called a cardiopulmonary bypass ...

In some cases, you may have lung granulomas that show no abnormal signs. They don’t usually need treatment or other testing. Granulomas are usually found during a doctor’s visit for something ...